Natera (NASDAQ:NTRA) CEO Sells $570,473.10 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,190 shares of the business’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $260.49, for a total transaction of $570,473.10. Following the completion of the sale, the chief executive officer owned 106,553 shares in the company, valued at approximately $27,755,990.97. This trade represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, July 28th, Steven Leonard Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $909,570.60.
• On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72.
• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The stock was sold at an average price of $206.16, for a total transaction of $185,956.32.

Natera Price Performance

Shares of NTRA stock traded up $1.60 during trading hours on Wednesday, hitting $253.82. The company had a trading volume of 925,147 shares, compared to its average volume of 1,091,572. The stock has a market capitalization of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. The company’s fifty day moving average is $244.16 and its 200 day moving average is $221.65. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04.

Hedge Funds Weigh In On Natera

Institutional investors have recently modified their holdings of the business. Horizon Investments LLC raised its position in Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its stake in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares during the period. Savvy Advisors Inc. grew its position in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after buying an additional 46 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares in the last quarter. Finally, First Horizon Corp increased its stake in shares of Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after buying an additional 51 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NTRA. Zacks Research lowered Natera from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. UBS Group set a $260.00 price objective on Natera in a report on Wednesday, June 24th. Guggenheim increased their target price on Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. BTIG Research set a $275.00 target price on Natera and gave the company a “buy” rating in a report on Wednesday, June 24th. Finally, Canaccord Genuity Group lifted their target price on Natera from $285.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.